ARTICLE | Clinical News

DAPD: Phase I/II

February 12, 2001 8:00 AM UTC

VIRS researchers reported that in a 14 day, open-label trial of DAPD at escalating doses, DAPD is rapidly absorbed and converted to its active metabolite, DXG. The plasma half-lives of DAPD and DXG were 1-2 and 7-9 hours, respectively, and pharmacokinetics did not significantly differ between treatment-naïve and experienced patients. ...